Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Brian Godman; Rickard E. Malmström; Eduardo Diogene; Andy Gray; Sisira Jayathissa; Angela Timoney; Francisco Acurcio; Ali Alkan; Anna Brzezinska; Anna Bucsics; Stephen M. Campbell; Jadwiga Czeczot; Winnie De Bruyn; Irene Eriksson; Faridah Aryani Md Yusof; Alexander E. Finlayson; Jurij Fürst; Kristina Garuoliene; Augusto Guerra Júnior; Jolanta Gulbinovič; Saira Jan; Roberta Joppi; Marija Kalaba; Einar Magnisson; Laura McCullagh; Kaisa Miikkulainen; Gabriela Ofierska-Sujkowska; Hanne Bak Pedersen; Gisbert Selke; Catherine Sermet; Susan Spillane; Azuwana Supian; Ilse Truter; Vera Vlahović-Palčevski; Low Ee Vien; Elif H. Vural; Janet Wale; Magdałene Władysiuk; Wenjie Zeng; Lars L. Gustafsson

doi:10.1586/17512433.2015.990380

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Brian Godman^*, Rickard E. Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Angela Timoney, Francisco Acurcio, Ali Alkan, Anna Brzezinska, Anna Bucsics, Stephen M. Campbell, Jadwiga Czeczot, Winnie De Bruyn, Irene Eriksson, Faridah Aryani Md Yusof, Alexander E. Finlayson, Jurij Fürst, Kristina Garuoliene, Augusto Guerra Júnior, Jolanta GulbinovičSaira Jan, Roberta Joppi, Marija Kalaba, Einar Magnisson, Laura McCullagh, Kaisa Miikkulainen, Gabriela Ofierska-Sujkowska, Hanne Bak Pedersen, Gisbert Selke, Catherine Sermet, Susan Spillane, Azuwana Supian, Ilse Truter, Vera Vlahović-Palčevski, Low Ee Vien, Elif H. Vural, Janet Wale, Magdałene Władysiuk, Wenjie Zeng, Lars L. Gustafsson

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

107 Citations (Scopus)

Abstract

Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

Original language	English
Pages (from-to)	77-94
Number of pages	18
Journal	Expert Review of Clinical Pharmacology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1586/17512433.2015.990380
Publication status	Published - 1 Jan 2014
Externally published	Yes

Keywords

clinical pharmacology
critical drug evaluation
dabigatran
differential pricing
ivacaftor
managed entry agreements
new models
rational use of medicines
sofosbuvir
trastuzumab emtansine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/17512433.2015.990380

Cite this

Godman, B., Malmström, R. E., Diogene, E., Gray, A., Jayathissa, S., Timoney, A., Acurcio, F., Alkan, A., Brzezinska, A., Bucsics, A., Campbell, S. M., Czeczot, J., De Bruyn, W., Eriksson, I., Yusof, F. A. M., Finlayson, A. E., Fürst, J., Garuoliene, K., Guerra Júnior, A., ... Gustafsson, L. L. (2014). Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Review of Clinical Pharmacology, 8(1), 77-94. https://doi.org/10.1586/17512433.2015.990380

@article{296fb3f2d8e243e78fbdb94fd6249f23,

title = "Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?",

abstract = "Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.",

keywords = "clinical pharmacology, critical drug evaluation, dabigatran, differential pricing, ivacaftor, managed entry agreements, new models, rational use of medicines, sofosbuvir, trastuzumab emtansine",

author = "Brian Godman and Malmstr{\"o}m, {Rickard E.} and Eduardo Diogene and Andy Gray and Sisira Jayathissa and Angela Timoney and Francisco Acurcio and Ali Alkan and Anna Brzezinska and Anna Bucsics and Campbell, {Stephen M.} and Jadwiga Czeczot and {De Bruyn}, Winnie and Irene Eriksson and Yusof, {Faridah Aryani Md} and Finlayson, {Alexander E.} and Jurij F{\"u}rst and Kristina Garuoliene and {Guerra J{\'u}nior}, Augusto and Jolanta Gulbinovi{\v c} and Saira Jan and Roberta Joppi and Marija Kalaba and Einar Magnisson and Laura McCullagh and Kaisa Miikkulainen and Gabriela Ofierska-Sujkowska and Pedersen, {Hanne Bak} and Gisbert Selke and Catherine Sermet and Susan Spillane and Azuwana Supian and Ilse Truter and Vera Vlahovi{\'c}-Pal{\v c}evski and Vien, {Low Ee} and Vural, {Elif H.} and Janet Wale and Magda{\l}ene W{\l}adysiuk and Wenjie Zeng and Gustafsson, {Lars L.}",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2014",

month = jan,

day = "1",

doi = "10.1586/17512433.2015.990380",

language = "English",

volume = "8",

pages = "77--94",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Godman, B, Malmström, RE, Diogene, E, Gray, A, Jayathissa, S, Timoney, A, Acurcio, F, Alkan, A, Brzezinska, A, Bucsics, A, Campbell, SM, Czeczot, J, De Bruyn, W, Eriksson, I, Yusof, FAM, Finlayson, AE, Fürst, J, Garuoliene, K, Guerra Júnior, A, Gulbinovič, J, Jan, S, Joppi, R, Kalaba, M, Magnisson, E, McCullagh, L, Miikkulainen, K, Ofierska-Sujkowska, G, Pedersen, HB, Selke, G, Sermet, C, Spillane, S, Supian, A, Truter, I, Vlahović-Palčevski, V, Vien, LE, Vural, EH, Wale, J, Władysiuk, M, Zeng, W & Gustafsson, LL 2014, 'Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?', Expert Review of Clinical Pharmacology, vol. 8, no. 1, pp. 77-94. https://doi.org/10.1586/17512433.2015.990380